Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 7/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MYLK | Q15746 | 1/20 | 0.50 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.50 |
| ▸ | XPO1 | O14980 | 2/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14927284 | 0.93 | KDM4E (0.55) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL898265 | 0.93 | P2RX1 (0.57) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL898584 | 0.89 | TMPRSS4 (0.50) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL898802 | 0.89 | DGAT1 (0.53) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL14927279 | 0.88 | KDM4E (0.54) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL16171175 | 0.88 | KDM4E (0.54) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL14927275 | 0.87 | KDM4E (0.45) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL14927282 | 0.83 | KDM4E (0.57) | KDM4EMAPTTMPRSS4P2RX1MCHR1 | |
| SCHEMBL14927274 | 0.82 | DGAT1 (0.46) | KDM4EMAPTTMPRSS4P2RX1P2RX4 | |
| SCHEMBL899044 | 0.82 | TMPRSS4 (0.57) | KDM4EMAPTTMPRSS4P2RX1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576532-B1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9663483-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC | 2016-01-28 | — | — | US | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8722731-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722731-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011156321-A9 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011156321-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, EIF4A1 | KDM4E 423/4885MAPT 4064/4885TMPRSS4 4354/4885 |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | KDM4E 369/4885MAPT 3803/4885TMPRSS4 4128/4885 |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | KDM4E 369/4885MAPT 3803/4885TMPRSS4 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.